Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
TRIB's Cash to Debt is ranked higher than
78% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. TRIB: No Debt )
TRIB' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: No Debt

Equity to Asset 0.82
TRIB's Equity to Asset is ranked higher than
86% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. TRIB: 0.82 )
TRIB' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.88
Current: 0.82

0.29
0.88
Interest Coverage 176.37
TRIB's Interest Coverage is ranked higher than
70% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. TRIB: 176.37 )
TRIB' s 10-Year Interest Coverage Range
Min: 0.73   Max: 9999.99
Current: 176.37

0.73
9999.99
F-Score: 5
Z-Score: 9.04
M-Score: -1.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 9.86
TRIB's Operating margin (%) is ranked higher than
84% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. TRIB: 9.86 )
TRIB' s 10-Year Operating margin (%) Range
Min: -56.78   Max: 21.86
Current: 9.86

-56.78
21.86
Net-margin (%) 10.57
TRIB's Net-margin (%) is ranked higher than
88% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. TRIB: 10.57 )
TRIB' s 10-Year Net-margin (%) Range
Min: -55.5   Max: 67.4
Current: 10.57

-55.5
67.4
ROE (%) 5.27
TRIB's ROE (%) is ranked higher than
71% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. TRIB: 5.27 )
TRIB' s 10-Year ROE (%) Range
Min: -118.02   Max: 42.76
Current: 5.27

-118.02
42.76
ROA (%) 4.26
TRIB's ROA (%) is ranked higher than
75% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. TRIB: 4.26 )
TRIB' s 10-Year ROA (%) Range
Min: -60.06   Max: 37.56
Current: 4.26

-60.06
37.56
ROC (Joel Greenblatt) (%) 19.37
TRIB's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. TRIB: 19.37 )
TRIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -200   Max: 54.55
Current: 19.37

-200
54.55
Revenue Growth (%) -2.80
TRIB's Revenue Growth (%) is ranked higher than
62% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. TRIB: -2.80 )
TRIB' s 10-Year Revenue Growth (%) Range
Min: -30.9   Max: 108.2
Current: -2.8

-30.9
108.2
EBITDA Growth (%) -42.20
TRIB's EBITDA Growth (%) is ranked higher than
53% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. TRIB: -42.20 )
TRIB' s 10-Year EBITDA Growth (%) Range
Min: -45.8   Max: 125.1
Current: -42.2

-45.8
125.1
EPS Growth (%) -47.60
TRIB's EPS Growth (%) is ranked higher than
52% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. TRIB: -47.60 )
TRIB' s 10-Year EPS Growth (%) Range
Min: -52.9   Max: 75.6
Current: -47.6

-52.9
75.6
» TRIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TRIB Guru Trades in Q3 2013

Jim Simons 508,200 sh (+25.47%)
Chuck Royce 342,000 sh (+1.85%)
» More
Q4 2013

TRIB Guru Trades in Q4 2013

Jim Simons 485,221 sh (-4.52%)
Chuck Royce 322,000 sh (-5.85%)
» More
Q1 2014

TRIB Guru Trades in Q1 2014

Jim Simons 450,272 sh (-7.2%)
Chuck Royce 278,924 sh (-13.38%)
» More
Q2 2014

TRIB Guru Trades in Q2 2014

Jim Simons 451,050 sh (+0.17%)
Chuck Royce 265,000 sh (-4.99%)
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2011-09-30 Sold Out 0.0026%$9.25 - $10.83 $ 21.81115%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 15.80
TRIB's P/E(ttm) is ranked higher than
91% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 15.80 )
TRIB' s 10-Year P/E(ttm) Range
Min: 2.08   Max: 47.8
Current: 15.8

2.08
47.8
P/B 0.66
TRIB's P/B is ranked higher than
99% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. TRIB: 0.66 )
TRIB' s 10-Year P/B Range
Min: 0.23   Max: 3.49
Current: 0.66

0.23
3.49
P/S 5.10
TRIB's P/S is ranked higher than
58% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. TRIB: 5.10 )
TRIB' s 10-Year P/S Range
Min: 0.16   Max: 5.57
Current: 5.1

0.16
5.57
EV-to-EBIT 47.71
TRIB's EV-to-EBIT is ranked higher than
75% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. TRIB: 47.71 )
TRIB' s 10-Year EV-to-EBIT Range
Min: 1   Max: 242.3
Current: 47.71

1
242.3
Shiller P/E 39.79
TRIB's Shiller P/E is ranked higher than
84% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 39.79 )
TRIB' s 10-Year Shiller P/E Range
Min: 2.02   Max: 1698
Current: 39.79

2.02
1698
Current Ratio 4.39
TRIB's Current Ratio is ranked higher than
83% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. TRIB: 4.39 )
TRIB' s 10-Year Current Ratio Range
Min: 1   Max: 9.17
Current: 4.39

1
9.17
Quick Ratio 2.46
TRIB's Quick Ratio is ranked higher than
72% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.47 vs. TRIB: 2.46 )
TRIB' s 10-Year Quick Ratio Range
Min: 0.44   Max: 7.6
Current: 2.46

0.44
7.6

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.01
TRIB's Dividend Yield is ranked higher than
92% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.26 vs. TRIB: 1.01 )
TRIB' s 10-Year Dividend Yield Range
Min: 0.92   Max: 1.33
Current: 1.01

0.92
1.33
Dividend Payout 0.50
TRIB's Dividend Payout is ranked higher than
84% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 0.50 )
TRIB' s 10-Year Dividend Payout Range
Min: 0.3   Max: 1.19
Current: 0.5

0.3
1.19
Yield on cost (5-Year) 1.00
TRIB's Yield on cost (5-Year) is ranked higher than
76% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. TRIB: 1.00 )
TRIB' s 10-Year Yield on cost (5-Year) Range
Min: 0.92   Max: 1.33
Current: 1

0.92
1.33
Share Buyback Rate -3.40
TRIB's Share Buyback Rate is ranked higher than
74% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. TRIB: -3.40 )
TRIB' s 10-Year Share Buyback Rate Range
Min: 26.2   Max: -79.2
Current: -3.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.14
TRIB's Price/Net Current Asset Value is ranked higher than
83% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 13.14 )
TRIB' s 10-Year Price/Net Current Asset Value Range
Min: 1.42   Max: 296
Current: 13.14

1.42
296
Price/Tangible Book 2.22
TRIB's Price/Tangible Book is ranked higher than
90% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.85 vs. TRIB: 2.22 )
TRIB' s 10-Year Price/Tangible Book Range
Min: 0.45   Max: 225
Current: 2.22

0.45
225
Price/DCF (Projected) 0.65
TRIB's Price/DCF (Projected) is ranked higher than
99% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 0.65 )
TRIB' s 10-Year Price/DCF (Projected) Range
Min: 0.38   Max: 78.35
Current: 0.65

0.38
78.35
Price/Median PS Value 1.63
TRIB's Price/Median PS Value is ranked higher than
67% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. TRIB: 1.63 )
TRIB' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 5.59
Current: 1.63

0.17
5.59
Price/Graham Number 0.84
TRIB's Price/Graham Number is ranked higher than
96% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 0.84 )
TRIB' s 10-Year Price/Graham Number Range
Min: 0.26   Max: 11.25
Current: 0.84

0.26
11.25
Earnings Yield (Greenblatt) 2.10
TRIB's Earnings Yield (Greenblatt) is ranked higher than
50% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. TRIB: 2.10 )
TRIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 96.3
Current: 2.1

0.4
96.3
Forward Rate of Return (Yacktman) 0.24
TRIB's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. TRIB: 0.24 )
TRIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -37.7   Max: 31.3
Current: 0.24

-37.7
31.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TRBA.Germany
Trinity Biotech PLC was incorporated as a public limited company, registered in Ireland in 1992. The Company commenced operations in 1992 and, in October 1992, completed an initial public offering of its securities in the US. The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. It is also a significant provider of raw materials to the life sciences industry. It sells over 278 products to customers in 110 countries through its own sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's tests remains the USA. The Company develops, acquires, manufactures and markets a wide range of clinical in-vitro diagnostic products. It supplies the clinical laboratory segment of the market with a range of diagnostic tests and instrumentation which detect infectious diseases, sexually transmitted diseases, blood coagulation and autoimmune disorders. It also sells raw materials to the life sciences industry. Point of Care refers to diagnostic tests which are carried out in the presence of the patient. Trinity Biotech's current range of POC tests mainly test for the presence of HIV antibodies. Its main product is UniGold HIV. UniGold, HIV has been used for several years in voluntary counselling and testing centres (VCTs) in sub-Saharan Africa where they provide a cornerstone to early detection and treatment intervention. Trinity Biotech sells its product through its own direct sales-force in four countries: the United States, Germany, France and the United Kingdom. Its competition includes several large companies such as, but not limited to, Roche, Abbott, Johnson & Johnson, Siemens (from the combined acquisitions of Bayer Diagnostics, Dade-Behring and DPC), Beckman Coulter, Inverness Medical Innovations, Inc., Bio-Rad and Thermo Fisher. The preclinical and clinical testing, manufacture, labelling, distribution, and promotion of Trinity Biotech's products are subject to extensive and rigorous government regulation in the United States and in other countries in which its products are sought to be marketed.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK